HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jain, A. Articles by Bozorgzadeh, A. Search for Related Content PubMed PubMed Citation Articles by Jain, A. Articles by Bozorgzadeh, A. Social Bookmarking                         What's this?

Pharmacokinetics of Mycophenolic Acid in Live Donor Liver Transplant Patients vs Deceased Donor Liver Transplant Patients

From the Department of Surgery, Division of Solid Organ Transplantation, University of Rochester Medical Center, Rochester, New York (Dr Jain, Dr Sharma, Dr Orloff, Dr Kashyap, Dr Tsoulfas, Dr Bozorgzadeh); School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (Dr Venkataramanan); Department of Laboratory Medicine, University of Rochester Medical Center, Rochester, New York (Dr Kwong); and Department of Surgery, University of Pennsylvania, Philadelphia (Dr Abt).

The exposure of mycophenolic acid in live donor liver transplant patients (those receiving a partial hepatic volume) in comparison to deceased donor liver transplant patients (those receiving the whole hepatic volume) after administration of mycophenolate mofetil has not been reported earlier. The aim of the present study is to compare the pharmacokinetics parameters of mycophenolic acid and mycophenolic acid glucuronide in live donor liver transplant patients versus deceased donor liver transplant patients. Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil. The maximum concentration (C_max) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (C_max/AUC: live donor liver transplant patients: 16.1 ± 6.6 µg/mL/43.9 ± 12.6 µg/mL·h vs deceased donor liver transplant patients: 10.7 ± 2.0 µg/mL/28.9 ± 7.1 µg/mL·h; P = .046/.002). The volume of distribution was higher in the deceased donor liver transplant patients compared with live donor liver transplant patients. However, the mean plasma concentration at 12 hours (C_last), drug disposition rate constant, half-life (t), and mean residence time were similar in both groups. The mean plasma concentration of mycophenolic acid glucuronide was 1.4 to 2.0 times higher in deceased donor liver transplant patients compared with live donor liver transplant patients. These observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplant patients.

Key Words: Liver transplantation • live donor • deceased donor • pharmacokinetics • mycophenolate mofetil • mycophenolic acid

Address for correspondence: Ashok Jain, MD, University of Rochester Medical Center, Department of Surgery, Division of Transplantation, 601 Elmwood Avenue, Box SURG, Rochester, NY 14642; e-mail: ashok_jain{at}urmc.rochester.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?